Leip, Eric P.

Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study

Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D’Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., et al. (2004) · Circulation

Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

Cited by 2,041

Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study

Wang, T. J., Larson, M. G., Levy, D., Vasan, R. S., Leip, E. P., Wolf, P. A., D’Agostino, R. B., Murabito, J. M., Kannel, W. B., & Benjamin, E. J. (2003) · Circulation

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 1,970

Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study

Franklin, S. S., Larson, M. G., Khan, S. A., Wong, N. D., Leip, E. P., Kannel, W. B., & Levy, D. (2001) · Circulation

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 1,390

Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age

Lloyd-Jones, D. M., Leip, E. P., Larson, M. G., D’Agostino, R. B., Beiser, A., Wilson, P. W. F., Wolf, P. A., & Levy, D. (2006) · Circulation

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 1,298

Impact of Obesity on Plasma Natriuretic Peptide Levels

Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Wilson, P. W. F., & Vasan, R. S. (2004) · Circulation

Heart Failure Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 1,022

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 664

Framingham risk score and prediction of lifetime risk for coronary heart disease

Lloyd-Jones, D. M., Wilson, P. W. F., Larson, M. G., Beiser, A., Leip, E. P., D'Agostino, R. B., & Levy, D. (2004) · The American Journal of Cardiology

Health Promotion and Cardiovascular PreventionCardiovascular Health and Risk Factors

Cited by 566

Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction: The Framingham Heart Study

Vasan, R. S., Benjamin, E. J., Larson, M. G., Leip, E. P., Wang, T. J., Wilson, P. W. F., & Levy, D. (2002) · JAMA

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 493

Glycemic Status and Development of Kidney Disease

Fox, C. S., Larson, M. G., Leip, E. P., Meigs, J. B., Wilson, P. W. F., & Levy, D. (2005) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 197

Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias

Kota, V., Brümmendorf, T. H., Gambacorti-Passerini, C., Lipton, J. H., Kim, D.-W., An, F., Leip, E., Crescenzo, R. J., Ferdinand, R., & Cortes, J. E. (2021) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 25